Biopharma
Connexius Vaccines Asia Conference 2027
- Date
- 23–24 June 2027
- Location
- Bangkok, Thailand
Event information
- Date
- 23–24 June 2027
- Location
- Bangkok, Thailand
Overview
Asia's vaccine industry is entering a new phase of growth, driven by investment in next-generation vaccine technologies, manufacturing capacity and regional vaccine security. Across the region, this momentum is already taking shape — from Thailand's efforts to strengthen domestic vaccine manufacturing and technology transfer, to new and expanded vaccine manufacturing capabilities in Singapore and South Korea.
Connexius Vaccines Asia Conference 2027, taking place on 23–24 June 2027 in Bangkok, Thailand, will bring together vaccine developers, manufacturers, biopharma leaders, regulators, government agencies and technology providers from across Asia.
The conference will explore the end-to-end vaccine journey — from discovery and clinical development to process development, manufacturing, CMC, regulatory, fill-finish and supply. Through strategic discussions, technical case studies, exhibition and networking, the conference will provide a dedicated platform to exchange expertise, explore emerging technologies and build partnerships that advance vaccine innovation and manufacturing across Asia.
Programme
Day 1 — Wednesday 23 June 2027
- 08:30
Registration & Welcome Coffee
- 09:00
Chairperson's Welcome & Opening Remarks
- 09:10
SESSION I - NEXT-GENERATION VACCINE INNOVATION
- 10:25
Morning Networking Break & Exhibition Viewing
- 11:10
SESSION II: PRECLINICAL & CLINICAL DEVELOPMENT
- 12:25
Networking Lunch & Exhibition Viewing
- 13:40
SESSION III: VACCINE PLATFORMS & FORMULATION
- 14:55
Afternoon Networking Coffee & Exhibition Viewing
- 15:40
SESSION IV: ANALYTICAL DEVELOPMENT, CMC & REGULATORY
- 17:00
End of Day 1 — Connexius Vaccines Asia 2027, Networking Reception
Day 2 — Thursday 24 June 2027
- 09:10
SESSION V: PROCESS DEVELOPMENT & SCALE-UP
- 10:25
Morning Networking Break & Exhibition Viewing
- 11:10
SESSION VI: UPSTREAM & DOWNSTREAM PROCESSING
- 12:25
Networking Lunch & Exhibition Viewing
- 13:40
SESSION VII: THE NEXT-GENERATION VACCINE FACTORY
- 14:55
Afternoon Networking Coffee & Exhibition Viewing
- 15:40
SESSION VIII: VACCINE COMMERCIALISATION, SUPPLY & SECURITY
- 17:00
End of Conference
Speakers

Associate Professor Pham Van Hung
Chairman
VABIOTECH
Vietnam

Dea Marsendah
Department Head of Bulk Conjugate Production
PT Bio Farma
Indonesia

Eriya Utaman, M.Sc
Vaccine Process Development Specialist
PT Bio Farma
Indonesia

Vanessa Gomez
Head of Vaccines
Sanofi
Philippines

Waranyoo Phoolcharoen, Ph.D
Chief Technical Officer and Co-Founder
Baiya Phytopharm
Thailand
Who Attends
By Company Profiles
- Vaccine Biopharma & Big Pharma50%
- Government, Regulators, Academia & Associations15%
- Solution & Service Providers30%
- Other Industry Stakeholders5%
By Job Functions
- Clinical Development & Medical Affairs15%
- Vaccine R&D / Discovery / Preclinical20%
- Process Development, Bioprocessing & MSAT20%
- CMC & Analytical Development8%
- Quality & Regulatory Affairs7%
- Supply Chain, Procurement & Tech Transfer7%
- Government, Public Health & Policy8%
- Business Development / Partnerships15%
By Country
- Thailand, Singapore, Malaysia, Indonesia & Vietnam65%
- South Korea, Japan, China & Taiwan20%
- India5%
- Other Asia / International10%
Media Partners
Want to Sponsor This Event?
Explore sponsorship opportunities and discover how your brand can connect with key decision-makers across the industry.
Speak with our Sponsorship Team
Register
Contact us for group bookings of three or more delegates.
| Delegate Category | Super Early Bird Rate Valid until 28th February 2027 | Early Bird Rate Valid 30th April 2027 | Standard Rate |
|---|---|---|---|
| Biopharma, Big Pharma, Academics, Research Institutes & Government | SGD 699 | SGD 899 | SGD 1,099 |
| Service & Solution Provider | SGD 2,049 | SGD 2,249 | SGD 2,449 |
INSIGHTS
Read before you go
- BiopharmaMarket insight
Genome Editing in Asia: Can the Region Turn CRISPR Science into Accessible Therapies?
The first approved CRISPR therapy proved that genome editing can work as a medicine. Asia, home to a large share of the world's patients with inherited blood disorders and a fast-growing research base, is now moving from discovery towards the clinic. This article looks at where the region stands, what is holding it back and what to watch next.
Read more: Genome Editing in Asia: Can the Region Turn CRISPR Science into Accessible Therapies? - BiopharmaIndustry article
Eppendorf Breaks Ground on a EUR 40 Million Production Site in Penang, Malaysia
On 12 November 2026, Eppendorf SE broke ground on a new production facility at Bandar Cassia Technology Park in Penang. The EUR 40 million investment is the company's first manufacturing operation in Southeast Asia and will produce selected products from its Centrifuges & Instruments portfolio for laboratories worldwide, with production starting gradually in 2028.
Read more: Eppendorf Breaks Ground on a EUR 40 Million Production Site in Penang, Malaysia - BiopharmaMarket insight
Could Four 2,000 L Single-Use Bioreactors Outperform One 10,000 L Stainless-Steel Reactor?
Biologics manufacturing productivity depends on more than installed bioreactor volume. This article compares four 2,000 L single-use bioreactors with one 10,000 L stainless-steel reactor and examines how turnaround time, utilisation, titre, downstream capacity and manufacturing strategy can determine annual output.
Read more: Could Four 2,000 L Single-Use Bioreactors Outperform One 10,000 L Stainless-Steel Reactor?



